使用Cerene冷冻消融装置行子宫内膜消融术后12个月时的宫腔镜进入与宫腔评估
这项前瞻性、多中心、单臂研究在子宫内膜消融术后12个月对223例受试者行诊断性宫腔镜,宫腔可进入220例(98.7%),可窥见宫腔204例(92.7%),其中95.6%的宫腔镜视野足以评估宫腔病理改变,无显著并发症。
要点
- 消融后12个月宫腔可进入率为98.7%(220/223)。
- 可窥见宫腔者中95.6%(195/204)的视野足以评估宫腔病理改变。
- 诊断性宫腔镜检查期间无显著并发症发生。
核心结论
- 这是迄今为止规模最大的宫腔镜评估消融后宫腔的研究;使用Cerene冷冻消融装置1年后在诊室行宫腔镜评估宫腔是可达成的,可在宫腔内完成诊断和治疗操作。
研究设计与样本
- 前瞻性、多中心、单臂研究,设置包括美国8个临床中心和加拿大2个中心及墨西哥1个中心的门诊医院环境。
- 共230例(242例中)受试者在第12个月访视时继续研究,其中223例可行诊断性宫腔镜评估。
- 受试者此前接受使用Cerene装置的2.5分钟子宫内膜冷冻消融,在第12个月随访时行诊断性宫腔镜。
主要发现
- 宫腔可进入220/223例(98.7%),不可进入3例(1.3%),原因为疼痛(n=2)和宫颈狭窄(n=1)。
- 宫腔可窥见204/220例(92.7%),其中一侧或双侧输卵管口可识别者占89.2%(182/204)。
- 双侧输卵管口均可见160/204例(78.4%),仅一侧可见22/204例(10.8%)。
- 剩余16/220例(7.2%)宫腔未窥见,原因为宫腔粘连(n=14)、技术困难(n=1)或月经(n=1)。
- 宫腔可窥见的204例中,195例(95.6%)的宫腔镜视野被判定足以评估宫腔病理改变;宫腔镜评估期间无显著并发症发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To evaluate whether physical access and the ability to systematically assess the postablation uterine cavity were preserved at 12 months after endometrial ablation with the Cerene cryotherapy device (ChannelMedsystems, Emeryville, CA). DESIGN: A prospective, multicenter, single-arm study. SETTING: In the clinic at 8 US sites and outpatient hospital setting at 2 sites in Canada and 1 site in Mexico. PATIENTS: A total of 230 (of 242) subjects continued in the study at the Month 12 visit after ablation. Two hundred twenty-three subjects were available for a diagnostic hysteroscopic evaluation. INTERVENTIONS: Subjects who had previously been treated with a 2.5-minute cryoablation of the endometrium utilizing the Cerene device underwent a diagnostic hysteroscopy at the Month 12 follow-up visit. MEASUREMENTS AND MAIN RESULTS: The uterine cavity was accessible in 220 of 223 subjects (98.7%) and not accessible in 3 (1.3%) because of pain (n = 2) and cervical stenosis (n = 1). Visualization of the uterine cavity was possible in 204 of 220 subjects (92.7%) with one or both tubal ostia identified in 89.2% (182 of 204) of subjects. Both tubal ostia were visible in 160 of 204 subjects (78.4%) and one ostium in 22 of 204 subjects (10.8%). The cavity was not visualized in the remaining 16 of 220 subjects (7.2%) because of intrauterine adhesions (n = 14), technical difficulties (n = 1), or menstruation (n = 1). In 95.6% (195 of 204) of subjects where the cavity was visualized, the hysteroscopic view was judged adequate to evaluate the uterine cavity for pathologic change. No significant complications occurred during the hysteroscopic evaluations. CONCLUSION: This is the largest study to date conducted to hysteroscopically evaluate the postablation uterine cavity. Uterine cavity assessment with in-office hysteroscopy 1 year after the use of the Cerene cryotherapy device is attainable, enabling both diagnostic and therapeutic procedures within the endometrial cavity.
引用
- Curlin H, Cholkeri-Singh A, Leal JGG, et al. Hysteroscopic Access and Uterine Cavity Evaluation 12 Months after Endometrial Ablation with the Cerene Cryotherapy Device. J Minim Invasive Gynecol. 2021. PMID: 34839060. doi:10.1016/j.jmig.2021.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。